CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 276,326 shares, an increase of 91.4% from the May 31st total of 144,356 shares. Based on an average daily volume of 459,271 shares, the short-interest ratio is presently 0.6 days. Currently, 3.0% of the shares of the stock are sold short.

CalciMedica Stock Performance

CALC stock remained flat at $0.97 during trading on Friday. 403,820 shares of the company traded hands, compared to its average volume of 3,529,546. The company has a 50 day simple moving average of $0.75 and a 200-day simple moving average of $1.82. CalciMedica has a 1 year low of $0.46 and a 1 year high of $7.20. The company has a market cap of $15.25 million, a PE ratio of -0.74 and a beta of 0.89.

Insider Activity

In related news, Director Fred A. Middleton bought 248,972 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was acquired at an average cost of $0.80 per share, with a total value of $199,177.60. Following the acquisition, the director owned 1,063,272 shares in the company, valued at approximately $850,617.60. This represents a 30.57% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 41.55% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CALC. Renaissance Technologies LLC grew its position in shares of CalciMedica by 45.0% during the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after buying an additional 39,775 shares during the period. 180 Wealth Advisors LLC boosted its stake in CalciMedica by 297.2% in the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after acquiring an additional 94,650 shares during the last quarter. Envestnet Asset Management Inc. grew its holdings in CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after acquiring an additional 34,386 shares during the period. Boothbay Fund Management LLC bought a new stake in shares of CalciMedica during the 4th quarter valued at $506,000. Finally, PVG Asset Management Corp acquired a new position in shares of CalciMedica in the 4th quarter valued at $302,000.

Analyst Upgrades and Downgrades

Separately, Oppenheimer dropped their target price on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, March 5th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $10.00.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.